暴露-反应效率建模,以支持在患有雷特综合征的个体中使用托菲尼提德剂量
Mona Darwish1, Julie Passarell2, James M Youakim3
1Acadia Pharmaceuticals Inc., 12830 El Camino Real, Suite 400, San Diego, CA, 92130, USA. mdarwish@ACADIA-Pharm.com.
Advances in therapy
|February 16, 2024
概括
托菲尼提德有效治疗雷特综合征,通过证明药物暴露与改善患者结果之间的明显联系. 这支持了当前对雷特综合征患者的托菲尼提德剂量方案.
科学领域:
- 药理学和治疗学 药理学和治疗学
- 神经发育障碍 神经发育障碍
- 临床试验分析
背景情况:
- 根据LAVENDER第3期研究数据,Trofinetide已被批准用于治疗雷特综合征 (RTT).
- 在这项研究中使用了基于体重的剂量方案.
- 暴露-反应 (ER) 建模用于分析药物疗效.
研究的目的:
- 在RTT患者中描述托菲尼提德暴露和疗效之间的关系.
- 为了支持使用E-R建模的批准的trofinetide剂量方案.
- 分析有效性终点,包括RSBQ,CGI-I,CSBS-DP-IT和RTT-COMC得分.
主要方法:
- 人口的药理动力学建模和贝叶斯估计被用来预测托菲尼提德暴露.
- 针对接受安慰剂或托菲尼提德的个人,开发了E-R模型.
- 关键的疗效终点包括雷特综合征行为问卷 (RSBQ) 和其他经过验证的尺度.
主要成果:
- 较高的托菲尼提德暴露与RSBQ,CSBS-DP-IT社会复合和RTT-COMC得分的改善相关.
- 目标AUC0-12值为800-1200μg·h/mL,与安慰剂相比,RSBQ得分的减少明显更大.
- 证实了CSBS-DP-IT社会复合和RTT-COMC的显著的ER关系.
结论:
- E-R 疗效建模证实了托菲尼提德暴露与关键 RTT 行为和沟通措施之间的显著关系.
- 托菲尼提德在目标暴露范围内显示出有效性.
- 这些发现支持对特洛菲尼提德在治疗雷特综合征的批准剂量方案.
相关概念视频
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:09Pharmacodynamic Models: Additive and Proportional Drug Effect Model
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).